Is the English Cancer Patient Experience Survey representative? A comparative analysis with the National Lung Cancer Audit

被引:8
|
作者
Nartey, Yvonne [1 ]
Stewart, Iain [2 ]
Khakwani, Aamir [1 ]
Beattie, Vanessa [3 ]
Wilcock, Andrew [4 ,5 ]
Woolhouse, Ian [6 ]
Beckett, Paul [7 ]
Hubbard, Richard B. [1 ]
Tata, Laila J. [1 ]
机构
[1] Univ Nottingham, Nottingham City Hosp, Div Epidemiol & Publ Hlth, Clin Sci Bldg, Nottingham NG5 1PB, England
[2] Univ Nottingham, Nottingham City Hosp, Div Resp Med, Clin Sci Bldg, Nottingham NG5 1PB, England
[3] Aintree Univ Hosp NHS Fdn Trust, Longmoor Lane, Liverpool L9 7AL, Merseyside, England
[4] Nottingham Univ Hosp, Hayward House, Nottingham, England
[5] Univ Nottingham, Nottingham, England
[6] Queen Elizabeth Hosp Birmingham, Mindelsohn Way, Birmingham B15 2GW, W Midlands, England
[7] Univ Hosp Derby & Burton NHS Fdn Trust, Uttoxeter Rd, Derby DE22 3NE, England
关键词
Patient experience; Patient view; CPES; Lung cancer; England; EUROPE; 1999-2007; CARE; QUALITY; SURVIVAL; PATTERNS; NONRESPONSE; IMPACT;
D O I
10.1016/j.lungcan.2019.11.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Healthcare systems increasingly recognise the importance of service users' perspectives for improving care organisation and delivery. The English Cancer Patient Experience Survey (CPES) is carried out annually, however, its representativeness within cancer types is unknown. We have explored if the CPES results are representative of people with lung cancer. Materials and methods: We linked cancer registry data across multiple sources to assess how CPES represents sociodemographic and clinical characteristics of the National Lung Cancer Audit population, accounting for post-sampling mortality bias. Multivariable logistic regression was used to compare people included and not included in CPES. Results: Of 240,375 people diagnosed (2009-2015), 15,967 (7 %) were included in CPES. Gender and ethnicity were reasonably represented, as were sociodemographic and clinical groupings, although more received anti-cancer treatment (96 % of CPES respondents vs. 56 % of patients nationally; adjusted odds ratio = 10.3, 95 confidence interval 9.4-11.2 for any anti-cancer treatment) with chemotherapy most over-represented, followed by surgery and then radiotherapy. CPES under-represented older, more socioeconomically deprived, and certain clinical groups, including those with worse performance status, multiple comorbidities, and diagnosis via emergency presentation. Conclusion: CPES includes patients across the sociodemographic and clinical spectrum indicating its value for research and service planning. Unbalanced representation of incident lung cancer cases is a limitation that must be considered in context of using CPES findings to implement service changes. Although half the national lung cancer population who received no anti-cancer treatment do not have their experiences represented, the strength of this dataset is in providing detailed comparisons of patient experiences across different treatment groups.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 50 条
  • [31] The Lung Cancer Patient Experience and Care Pathway: A Multi-Country Survey
    Frank, P.
    Ciupek, A.
    Varriale, P.
    Laurent, J.
    Bar Ziv, O.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S105 - S106
  • [33] Victorian Comprehensive Cancer Centre Lung Cancer Clinical Audit: Collecting the UK National Lung Cancer Audit data from hospitals in Australia
    Mileshkin, Linda
    Waterhouse, Tamsin
    Cross, Hannah
    Duffy, Mary
    Nelson, Paula
    Shaw, Mark
    Mitchell, Paul
    Akhurst, Tim
    Irving, Louis
    Conron, Matthew
    Moore, Melissa
    Philip, Jennifer
    Barnett, Stephen
    Antippa, Philip
    Bartlett, James
    Emery, Jon
    Byrne, Jennifer
    Bishop, Jim
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1106 - S1107
  • [34] Characteristics of female lung cancer in Korea: analysis of Korean National Lung Cancer Registry
    Lim, Jeong Uk
    Han, Solji
    Kim, Ho Cheol
    Choi, Chang Min
    Jung, Chi Young
    Cho, Deog Gon
    Jeon, Jae Hyun
    Lee, Jeong Eun
    Ahn, Jin Seok
    Kim, Yeongdae
    Choi, Yoo-Duk
    Suh, Yang-Gun
    Kim, Jung-Eun
    Won, Young-Joo
    Kim, Young-Chul
    Park, Chan Kwon
    Kim, Seung Joon
    JOURNAL OF THORACIC DISEASE, 2020, 12 (09) : 4612 - +
  • [35] MALIGNANT PLEURAL MESOTHELIOMA IN THE UK NATIONAL LUNG CANCER AUDIT: AN ANALYSIS OF 8503 CASES
    Peake, Michael D.
    Beckett, Paul
    Woolhouse, Ian
    Stanley, Roz
    Fennell, Dean
    Edwards, John
    Hubbard, Richard
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S311 - S311
  • [36] The National Lung Cancer Audit: The Impact of COVID-19
    Conibear, J.
    Nossiter, J.
    Foster, C.
    West, D.
    Cromwell, D.
    Navani, N.
    CLINICAL ONCOLOGY, 2022, 34 (11) : 701 - 707
  • [37] ARE LUNG CANCER TREATMENT AND SURVIVAL RATES IMPROVING IN THE UK? RESULTS FROM THE NATIONAL LUNG CANCER AUDIT
    Woolhouse, Ian
    Beckett, Paul
    Stanley, Roz
    Peake, Michael D.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1417 - S1417
  • [38] Reliability of hospital scores for the Cancer Patient Experience Survey: analysis of publicly reported patient survey data
    Abel, Gary A.
    Gomez-Cano, Mayam
    Tra My Pham
    Lyratzopoulos, Georgios
    BMJ OPEN, 2019, 9 (07):
  • [39] Cancer care in a time of COVID: lung cancer patient's experience of telehealth and connectedness
    Fraser, Anne
    McNeill, Rob
    Robinson, Jackie
    SUPPORTIVE CARE IN CANCER, 2022, 30 (02) : 1823 - 1830
  • [40] A national audit of radiology practice in cancer multidisciplinary team meetings
    Balasubramaniam, R.
    Drinkwater, K.
    Howlett, D. C.
    CLINICAL RADIOLOGY, 2020, 75 (08)